TICKERNERD
Menu
CATXCATXHealthcare · Medical Devices

CATX Stock Forecast: Perspective Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$2.71
+10.16% on the day

The 16 Wall Street analysts covering Perspective Therapeutics, Inc. hold a median 12-month price target of $13 — +379.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$309.4M
Ticker Nerd rank
36 / 100
Median analyst target
$13
Analysts covering
16
Revenue$0.0
Operating income−$29.3M
Net income−$26.8M
Free cash flow−$34.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.4%
1M
−13.1%
YTD
−1.5%
1Y
−29.8%
From 52W high
−52.0%
From 52W low
+32.2%
$2.05
$5.65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CATX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Perspective Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
70
Volatility
65
Size
61
Quality
60
Value
44
Momentum
41
Accruals
36
Growth
20
Issuance
18

Revisions (70): Analysts have, on balance, been raising their forecasts.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CATX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CATX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26CATXHigh $18Median $13Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
15 Buy1 Hold0 Sell
Low $5Median $13High $18

The green dot is the last close — the median target sits +379.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Oct 2026BTIGReiteratesBuy—
18 Sept 2026William BlairInitiatesOutperform—
15 Sept 2026WedbushReiteratesOutperform—
19 Aug 2026BMO CapitalInitiatesOutperform—
14 Aug 2026B of A SecuritiesMaintainsNeutral—
11 Aug 2026Piper SandlerMaintainsOverweight—
5 May 2026BTIGReiteratesBuy—
5 May 2026WedbushReiteratesOutperform—
20 Apr 2026WedbushReiteratesOutperform—
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
18 Mar 2026B. Riley SecuritiesMaintainsBuy—
18 Mar 2026UBSMaintainsBuy—
18 Mar 2026WedbushReiteratesOutperform—
17 Mar 2026BTIGReiteratesBuy—
17 Mar 2026RBC CapitalMaintainsOutperform—
19 Feb 2026Piper SandlerInitiatesOverweight—
30 Jan 2026HC Wainwright & Co.MaintainsBuy—
30 Jan 2026WedbushReiteratesOutperform—
13 Jan 2026BTIGReiteratesBuy—
21 Nov 2025UBSMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CATX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CATX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Perspective Therapeutics, Inc. returned −29.8% against +16.2% for the S&P 500, dividends included.

CATX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26CATXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CATX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Perspective Therapeutics, Inc. (CATX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 86% of US stocks

Price / sales
756.4×

Cheaper than 1% of US stocks

Price / book
1.0×

Cheaper than 73% of US stocks

EV / EBITDA
−0.6×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
−72.1%

Higher than 3% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−36121.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−39.6%

Higher than 24% of US stocks

Return on assets
−22.3%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Perspective Therapeutics, Inc. (CATX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Perspective Therapeutics, Inc. has a market value of $309.4M and an enterprise value of $76.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0. The latest quarter shrank 72.1% year on year.

  • Net income over the same four quarters: −$116.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$121.2M.

  • Shares outstanding: 114.1M.

  • Trailing P/E: −1.9×; forward P/E: −2.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Perspective Therapeutics, Inc. employs 163 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

CATX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CATXPerspective Therapeutics, Inc.$309.4M
36
CLPTClearpoint Neuro, Inc.$312.1M
20
MOBIMobia Medical, Inc.$283.2M
2
CVCapsoVision, Inc.$352.3M
20
OFIXOrthofix Medical, Inc.$356.4M
71
INFUInfuSystem Holdings, Inc.$267.1M
100
VMDViemed Healthcare, Inc.$357.7M
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Perspective Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CATX news & analysis

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

GlobeNewsWire · 8 Oct 2026positive

Perspective Therapeutics said the FDA granted Fast Track Designation for development of [212Pb]PSV359 in adults with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.

Why it matters — The designation is a regulatory development for CATX’s PSV359 program in this patient population.

Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium

GlobeNewsWire · 7 Oct 2026positive

Perspective Therapeutics announced that data from its [²¹²Pb]VMT-α-NET program were accepted for presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium, scheduled for November 5–7, 2026, in Las Vegas.

Why it matters — The acceptance places data from CATX’s [²¹²Pb]VMT-α-NET program on the agenda for a 2026 medical symposium.

Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026

GlobeNewsWire · 2 Oct 2026positive

Perspective Therapeutics announced that data from its lapemelanotide zapixetar ([212Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, scheduled for November 4-8, 2026, in Phoenix, Arizona. SITC plans to release further abstract details on November 3, 2026.

Why it matters — A CATX watcher would care because acceptance of the company's radiopharmaceutical data at a major cancer immunotherapy conference signals growing recognition of its pipeline progress and provides an upcoming opportunity to see clinical results.

This $3 Biotech Could Be Worth $11.45, Analyst Says

Benzinga · 18 Sept 2026positive

William Blair expressed a positive view on Perspective Therapeutics (CATX), suggesting the company could benefit from growing interest in radiopharmaceutical cancer treatments. The analyst reportedly sees upside potential for the stock, though specific price targets or figures were not detailed.

Why it matters — The analyst's positive outlook highlights growing interest in radiopharmaceutical cancer treatments, a key area for CATX that could draw investor attention.

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

GlobeNewsWire · 14 Sept 2026positive

Perspective Therapeutics announced a clinical trial collaboration and supply agreement with Merck to evaluate its radiopharmaceutical [212Pb]PSV359 in combination with Keytruda (pembrolizumab) in FAP-α positive solid tumors. The collaboration is part of Perspective's work as a radiopharmaceutical development company advancing cancer treatments.

Why it matters — A CATX watcher would care because the agreement with Merck lends external validation and potential development support for Perspective's lead investigational radiopharmaceutical candidate in combination with a widely used immunotherapy.

FAQ

Frequently asked questions about CATX stock

What is the CATX stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Perspective Therapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $5 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CATX stock a buy right now?

Of the 16 analysts covering Perspective Therapeutics, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Perspective Therapeutics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CATX?

As at 8 Oct 2026, Perspective Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (70 of 100).

Will CATX stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +379.7% from the last close, and Ticker Nerd's factor model ranks Perspective Therapeutics, Inc. 36 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CATX stock forecast for 2030?

No analyst covering Perspective Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CATX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $18 over the next 12 months.

How has CATX stock performed over the past year?

Perspective Therapeutics, Inc. returned -29.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Perspective Therapeutics, Inc. do?

Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer.

What is the latest news on CATX?

The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors". Perspective Therapeutics said the FDA granted Fast Track Designation for development of [212Pb]PSV359 in adults with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.

Company

About Perspective Therapeutics, Inc.

Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care. Its programs are built around proprietary lead-212-based technology and a theranostic approach that combines diagnosis and treatment in a single oncology platform. Perspective Therapeutics is active in several cancer areas, including neuroendocrine tumors, metastatic melanoma, and other solid tumors, through its clinical-stage development efforts. The company also works on complementary tools and manufacturing capabilities that support its radiopharmaceutical pipeline and clinical operations. Based in Seattle, Perspective Therapeutics plays a specialized role in the broader oncology market by advancing targeted nuclear medicine approaches for cancer care.

CEO Mr. Johan M. Spoor · 163 employees · United States · https://www.perspectivetherapeutics.com